机构:[1]Fudan Univ, Shanghai Pudong Hosp, Dept Gen Surg, Pudong Med Ctr, 2800 Gongwei Rd, Shanghai 201399, Peoples R China[2]Hebei Med Univ, Dept Gen Surg, Hosp 4, Shijiazhuang 05001, Hebei, Peoples R China河北医科大学第四医院[3]Fudan Univ, Shanghai Pudong Hosp, Ctr Med Res & Innovat, Pudong Med Ctr, 2800 Gongwei Rd, Shanghai 201399, Peoples R China[4]Fudan Univ, Shanghai Pudong Hosp, Dept Med Oncol, Pudong Med Ctr, Shanghai 201399, Peoples R China
Background: Liver cancer was the fourth leading cause of cancer-related death in 2015. Hepatocellular carcinoma (HCC) is the most common type of liver cancer. miR-1-3p plays important roles in cancer, including prostate, bladder, lung cancer, and colorectal carcinoma. The function of miR-1-3p in HCC remains poorly understood. Methods: qRT-PCR was performed to detect the miR-1-3p expression in HCC cell lines (HCCLM3, Hep3B, Bel-7404, SMMC-7721) and the normal human hepatic cell line (LO2). HCCLM3 and Bel-7404 cells were transfected with miR-1-3p mimic or scramble control followed by water-soluble tetrazolium salt (WST-1) assay. Western bolt analysis was performed to determine the protein levels. TargetScan7.1 (http://www.targetscan.org/vert_71/) was used to predict the potential targets of miR-1-3p. SRY (sex determining region Y)-box 9 (S OX9), which has been previously shown to play an important role in HCC, was found to be a target of miR-1-3p. Luciferase reporter assay was used to explore the targeting of miR-1-3p on SOX9. For in vivo tumorigenesis assay, HCCLM3 cells with stable overexpression of miR-1-3p or control plasmid were injected subcutaneously into the flank of the SCID mice and animals were monitored for tumor growth. Results: miR-1-3p was significantly downregulated in HCC cell lines (HCCLM3, Hep3B, Bel-7404, and SMMC-7721) compared to normal human hepatic cell line (LO2). Overexpression of miR-1-3p significantly inhibited the proliferation and induced apoptosis in HCCLM3 and Bel-7474 cells. SOX9 was a direct target of miR-1-3p in HCC cells. Inhibition of SOX9 significantly inhibited the proliferation of HCCLM3 and Bel-7474 cells. In vivo, overexpression of miR-1-3p decreased tumor volume in a xenograft model. Conclusion: These results highlight the role of miR-1-3p in HCC. Overexpression of miR-1-3P inhibited the proliferation of HCC at least partly due to the regulation of SOX9. miR-1-3p may be a promising therapeutic candidate for HCC.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81572518, 81372750]; Academic Leaders Training Program of Pudong Health Bureau of Shanghai [PWRd2018-07]; Clinical Plateau Discipline Project of Pudong Health Bureau of Shanghai [PWYgy2018-08]; International Technology Cooperation Project of Hebei Provincial Department of Science Technology [13397708D]
第一作者机构:[1]Fudan Univ, Shanghai Pudong Hosp, Dept Gen Surg, Pudong Med Ctr, 2800 Gongwei Rd, Shanghai 201399, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Fudan Univ, Shanghai Pudong Hosp, Dept Gen Surg, Pudong Med Ctr, 2800 Gongwei Rd, Shanghai 201399, Peoples R China[3]Fudan Univ, Shanghai Pudong Hosp, Ctr Med Res & Innovat, Pudong Med Ctr, 2800 Gongwei Rd, Shanghai 201399, Peoples R China[*1]Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Shanghai 201399, People’s Republic of China[*2]Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Shanghai 201399, People’s Republic of China
推荐引用方式(GB/T 7714):
Zhang Hao,Zhang Zhenya,Gao Lili,et al.miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9[J].ONCOTARGETS AND THERAPY.2019,12:2149-2157.doi:10.2147/OTT.S197326.
APA:
Zhang, Hao,Zhang, Zhenya,Gao, Lili,Qiao, Zhengdong,Yu, Minghua...&Yang, Tao.(2019).miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.ONCOTARGETS AND THERAPY,12,
MLA:
Zhang, Hao,et al."miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9".ONCOTARGETS AND THERAPY 12.(2019):2149-2157